Paula Ragan Sells 49,678 Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Stock

X4 Pharmaceuticals, Inc. (NASDAQ:XFORGet Free Report) CEO Paula Ragan sold 49,678 shares of the business’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $0.88, for a total value of $43,716.64. Following the completion of the sale, the chief executive officer now owns 765,068 shares in the company, valued at $673,259.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Paula Ragan also recently made the following trade(s):

  • On Monday, February 12th, Paula Ragan sold 21,695 shares of X4 Pharmaceuticals stock. The shares were sold at an average price of $1.01, for a total value of $21,911.95.

X4 Pharmaceuticals Price Performance

Shares of XFOR stock traded up $0.03 during mid-day trading on Monday, hitting $0.91. The company had a trading volume of 1,795,123 shares, compared to its average volume of 1,325,463. The stock’s 50 day moving average price is $0.87 and its 200-day moving average price is $0.90. The company has a debt-to-equity ratio of 0.80, a current ratio of 5.81 and a quick ratio of 5.81. The company has a market capitalization of $152.70 million, a P/E ratio of -1.16 and a beta of 0.44. X4 Pharmaceuticals, Inc. has a 52-week low of $0.57 and a 52-week high of $2.58.

Analysts Set New Price Targets

Separately, B. Riley cut X4 Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $3.00 to $1.00 in a research report on Tuesday, December 12th.

Check Out Our Latest Stock Analysis on XFOR

Hedge Funds Weigh In On X4 Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. Principal Financial Group Inc. bought a new position in X4 Pharmaceuticals in the 2nd quarter worth about $27,000. ProShare Advisors LLC bought a new position in X4 Pharmaceuticals in the 2nd quarter worth about $31,000. Bayesian Capital Management LP bought a new position in X4 Pharmaceuticals in the 4th quarter worth about $33,000. SG Americas Securities LLC bought a new position in X4 Pharmaceuticals in the 3rd quarter worth about $37,000. Finally, Private Advisor Group LLC bought a new position in X4 Pharmaceuticals in the 2nd quarter worth about $38,000. 78.50% of the stock is currently owned by institutional investors.

X4 Pharmaceuticals Company Profile

(Get Free Report)

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia.

Read More

Insider Buying and Selling by Quarter for X4 Pharmaceuticals (NASDAQ:XFOR)

Receive News & Ratings for X4 Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for X4 Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.